This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.